Shin Poong Pharm acquires approval of its modified drug, Pyramax’
Shin Poong Pharm(CEO Jae-man Yoo) announced approval of its incrementally modified drug, a child malaria treatment ‘Pyramax Gran’ having pyronaridine phosphate as a main substance from the Ministry of Food and Drug Safety.
Pyramax Gran and Pyramax Tab, products jointly developed by Shin Poong P...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.